ObjectiveThis annual conference aims at keeping legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments, legislative initiatives and case law. A particular focus will be on implications for the sector of recent EU activities in the fields of competition law, intellectual property, data protection and privacy as well as pharmaceutical law.Key topicsCompetition law and patentsReverse payment settlements in the US and in Europe and current activities from the European Commission in the field of competition lawInterim and cross-border injunctions against infringement of pharmaceutical patentsPreparing for the EU unitary patent system: update on recent developmentsData protection and privacyAccess to clinical trials data: the General Court decision in InterMune (T-73/13R)Proposal for modification of the General Data Protection Regulation (COM(2012)11): implications for the life science sectorCloud computing health services and data protectionEU pharmaceutical law round-upUpdate on EU legislative proposals: clinical trials, in vitro diagnostics, orphan drugsMajor developments in the fight against falsified medicinal productsDrug device combination products and data exclusivity Off-label use and the CJEU case Novartis Pharma v Apozyt (C-535/11)Orphan medicinal products and the recent decision in Laboratoires CTRS (T-301/12)SpeakersIan Dodds-Smith, Lawyer, Arnold & Porter LLP, London Jean Herveg, Member of Brussels Bar; Head of Research, CRIDS, University of Namur David Hull, Partner, Van Bael & Bellis, Brussels Philippe de Jong, Partner, Altius, Brussels Stefano Marino, Head of Legal Department, European Medicines Agency (EMA), London Geneviève Michaux, Counsel, Hunton & Williams, Brussels Harald Mische, Antitrust: Pharma and Health Services Unit, DG Competition, European Commission, Brussels Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Brussels Kristof Roox, Partner, Crowell & Moring LLP, Brussels David Rosenberg, VP, Corporate IP Policy, GlaxoSmithKline (UK); IP Policy Committee Chair, EFPIA, Brussels Florian Schmidt, Legal Officer, DG SANCO, European Commission, Brussels Kristof Van Quathem, Data Protection Advisor, Covington & Burling LLP, Brussels